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The purpose of this study was to determine activity of temozolomide combined with paclitaxel or epothilone B in vitro, and to
investigate the combination of temozolomide with paclitaxel in a Phase I clinical trial. Melanoma cell lines A375P and DX3 were
treated with temozolomide and either paclitaxel or epothilone B. Combination indices were determined to assess the degree of
synergism. In a clinical study, 21 patients with malignant melanoma were treated with increasing doses of temozolomide (orally, days
1–5), in combination with a fixed dose of paclitaxel (i.v. infusion day 1), followed by dose escalation of the latter drug. Cycles of
treatment were repeated every 3 weeks. Pharmacokinetics of both agents were determined on day 1, with temozolomide
pharmacokinetics also assessed on day 5. All three compounds were active against the melanoma cell lines, with epothilone B being
the most potent. There was a strong degree of synergism between temozolomide and either paclitaxel or epothilone B. In the clinical
study, no pharmacokinetic interaction was observed between temozolomide and paclitaxel. Dose escalation of both drugs to clinically
active doses was possible, with no dose-limiting toxicities observed at 200mgm
 2day
 1 temozolomide and 225mgm
 2day
 1
paclitaxel. There were two partial responses out of 15 evaluable patients. One patient remains alive and symptom-free at 4 years
after treatment. Temozolomide and paclitaxel may be administered safely at clinically effective doses. Further evaluation of these
combinations in melanoma is warranted.
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Stage IV melanoma carries a very poor prognosis (Balch et al,
2001) and a median survival of no more than 6–9 months. The 5-
year survival is at best 5–10% (Lotze et al, 2001). Several drugs
have been used in the treatment of stage IV melanoma, including
dacarbazine (DTIC), nitrosoureas, platinum compounds and vinca
alkaloids, with only modest success.
Paclitaxel (Taxolt) is a member of the taxane group of
antitumour agents. It was discovered in the early sixties by the
National Cancer Institute (Rowinsky and Donehower, 1995). Early
clinical studies indicated activity against a number of tumours
including ovarian, breast, lung and melanoma (Rowinsky et al,
1990; Einzig et al, 1991b; Ettinger, 1993; Martin, 1993). Paclitaxel
was first approved by the FDA in 1992 to be used as a second-line
treatment for ovarian carcinoma (Arbuck et al, 1993). Against
metastatic malignant melanoma, paclitaxel has a response rate of
18–20% (Legha et al, 1990; Einzig et al, 1991a; Wiernik and Einzig,
1993). Paclitaxel exerts its antitumour activity by binding to the b
subunit of tubulin (Horwitz, 1994) and stabilising microtubules.
The mechanisms by which cells become resistant to paclitaxel are
thought to be either due to mutations in tubulin or to over-
expression of drug efflux pumps such as MDR1. The main
toxicities associated with paclitaxel are: hypersensitivity reactions,
neutropaenia and peripheral neuropathy, usually sensory.
Temozolomide (Temodalt) is an oral alkylating agent, related to
DTIC. After administration, temozolomide spontaneously decom-
poses to 5-(3-methyltriazen-l-yl)imidazole-4-carboxamide (MTIC),
which then yields AIC and methyl diazonium (Denny et al, 1994).
The latter alkylates DNA, primarily at the O
6 of guanine.
Bioavailability of temozolomide is nearly 100% when administered
orally, with good distribution to tissue (Baker et al, 1999; Brada
et al, 1999). Activity has been demonstrated against a number of
tumours (Bleehen et al, 1995; Dhodapkar et al, 1997; Middleton
et al, 2000b). In malignant melanoma, activity was comparable to
that of dacarbazine (Middleton et al, 2000a,b).
Cancer cells may acquire resistance to temozolomide by a
number of mechanisms, including overexpression of O
6-alkylgua-
nine-DNA alkyltransferase (Lee et al, 1994; Middleton et al, 1998),
deficiency or mutation in the mismatch repair (MMR) pathway
(D’Atri et al, 1998) and increased expression of proteins that
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sinhibit apoptosis, such as Bcl-2 (Selzer et al, 1998). Temozolomide
is well tolerated (Newlands et al, 1992; O’Reilly et al, 1993; Bleehen
et al, 1995; Dhodapkar et al, 1997), with thrombocytopaenia as the
main toxicity. This is usually self-limiting and most patients
recover by day 28.
Individually, paclitaxel and temozolomide have modest activity
against metastatic malignant melanoma. As they have different
mechanisms of action, nonoverlapping toxicities and differing
mechanisms of resistance, the combination of paclitaxel and
temozolomide has been investigated in a Phase I study in
melanoma patients. In addition to the clinical trial, in vitro growth
inhibition studies were performed with the combination of
temozolomide and either paclitaxel or epothilone B, a novel
antimicrotubule compound (Rothermel et al, 2003).
METHODS
In vitro studies
Two melanoma cell lines, A375P and DX3, were cultured using
RPMI 1640 culture medium with L-glutamine supplemented with
10% foetal calf serum and penicillin/streptomycin in 5% CO2
incubators at 371C. Cells were exposed to varying concentrations
of temozolomide, paclitaxel or epothilone B individually for three
doubling times and IC50 values determined in triplicate using the
SRB assay.
Drug combination studies were conducted on each cell line
using either temozolomide plus paclitaxel or temozolomide plus
epothilone B. In each case, cells were exposed to the two agents
simultaneously. Drug concentrations used in combination were at
3, 1, 0.3, 0.1, 0.01 times the IC50 concentration for each drug. Data
were analysed using the Calcusyn software and the method of Chou
and Hayball (1996). The combination index (CI) for each drug
combination was calculated, where CI¼1 denotes an additive effect,
CIo1 indicates synergy and CI41 suggests antagonism of effect.
Clinical study
The primary objectives of the study were to determine the
maximum tolerated dose of the combination of paclitaxel and
temozolomide, and to identify the haematological and nonhaema-
tological toxicities of the combination. Secondary objectives were
to determine the response rate and response duration from the
combination, and to determine the pharmacokinetics of temozo-
lomide and paclitaxel when given in combination.
Adult patients with a diagnosis of stage IV melanoma were
included. All were chemotherapy naı ¨ve, with no clinical evidence
of CNS metastases, WHO performance status of 0–2, a life
expectancy of at least 12 weeks and adequate haematological, renal
and hepatic function. Patients had at least one measurable lesion.
All patients signed an informed consent form prior to participating
in the trial, which was approved by the ethics committee of the
Newcastle Hospitals Trust and of the Medical School, University of
Kingston upon Hull. All patients had prestudy biochemical,
clinical and radiological assessments before receiving the first
cycle of chemotherapy and subsequently during the study.
Toxicities were assessed using the Common Toxicity Criteria
(Version 2.0).
Dose levels for the study were predefined as in Figure 1;
however, intermediate dose levels were allowed. Paclitaxel was
MTD = maximum tolerated dose 
Temozolomide 100 mg m
−2 day
−1
Paclitaxel 150 mg m
−2
Temozolomide 150 mg m
−2 day
−1
 Paclitaxel 150 mg m
−2
Temozolomide 200 mg m
−2 day
−1
Paclitaxel 150 mg m
−2
Temozolomide 200 mg m
−2 day
−1
Paclitaxel 175 mg m
−2
Temozolomide 200 mg m
−2 day
−1
Paclitaxel 200 mg m
−2
Temozolomide 200 mg m
−2 day
−1
Paclitaxel 225 mg m
−2
Temozolomide 150 mg m
−2 day
−1
Paclitaxel 200 mg m
−2
Temozolomide 150 mg m
−2 day
−1










Figure 1 Dose escalation scheme, indicating daily dose of temozolomide, given on each of 5 consecutive days. Dose of paclitaxel administered on day 1.
The dose levels used in the current study are indicated by number. Dose level 4 represents full therapeutic doses of each agent. After dose level 4,
subsequent dose changes depended on the occurrence of dose-limiting toxicities to define the maximum tolerated dose (MTD).
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sadministered intravenously as a 3-h infusion on day one of each
cycle. Standard premedications were used to prevent hypersensi-
tivity reactions. Temozolomide was given orally on the morning of
days 1–5 at least 1h before or 2h after breakfast. Post
chemotherapy, emesis was treated prophylactically, with ondanse-
tron or metoclopramide orally.
On day 1 of cycle 1, blood samples (5ml) for analysis of
temozolomide were collected in pre-chilled heparinised tubes at
10, 20, 30, 60, 90, 120, 150, 180, 240, 360 and 1320min after
administration of temozolomide, plasma was separated and 2ml
was transferred to a plastic tube containing 0.1ml of 8.5%
phosphoric acid. For analysis of paclitaxel, 5ml heparinised blood
samples were taken pretreatment and at 90, 180, 185, 195, 210, 225,
240, 270, 300, 360, 420, 540, 1260 and 1620min from the start of
infusion. Sampling for temozolomide pharmacokinetics was
repeated on day 5 of cycle 1. Determinations of concentrations
of paclitaxel or temozolomide in plasma were performed by HPLC,
as previously described (Siddiqui et al, 1997; Estlin et al, 1998).
RESULTS
In vitro studies
Against the two melanoma cell lines, paclitaxel and temozolomide
had very different activity. Values for IC50 (mean7s.d.) for
temozolomide (8357110 and 821775mM) and paclitaxel
(15.372.5nM and 13.571.5nM) were similar for the DX3 and
A375P cell lines. The cell lines were 30- to 40-fold more sensitive to
epothilone B, with IC50 values of 0.5570.06 and 0.3170.05nM
against DX3 and A375P cells, respectively.
For the DX3 cell line, the combination of temozolomide with
paclitaxel produced CI values ranging from 0.02 at a fractional
effect (FE) of 0.65 to a CI of 0.4 at an FE of 0.95. Corresponding
values for the DX3 cells with temozolomide and epothilone B were
CI¼0.01 (FE¼0.84) and CI¼0.55 (FE¼0.96). In the A375P cell
line, temozolomide plus paclitaxel produced a CI of 0.15 at an FE
of 0.1 and 0.66 at an FE of 0.9. Corresponding values for the
combination with epothilone in the A375P cells were CI¼0.07
(FE¼0.05) and CI¼0.79 (FE¼0.98). Taken together, these data
suggest synergism of action of these drug combinations against
these two melanoma cell lines.
Clinical study
A total of 22 patients (13 male and nine female subjects) with a
median age of 52.5 years (range 29–69 years) were recruited into
the clinical study (Table 1). Patients received a total of 61 cycles of
the combination chemotherapy, with an average of 2.8 cycles per
patient. A total of 17 patients were assessable for toxicities and 15
patients were assessable for disease response. Six dose levels were
explored (Figure 1).
Four patients were withdrawn from the study due to develop-
ment of brain metastases within 28 days of enrolment. One patient
was consented and did not receive treatment due to bleeding skin
lesions and one patient progressed clinically and was taken off
study after 22 days. One patient with apparently recurrent disease
was found, on review of CT scans after six cycles of treatment, to
have simple liver cysts.
Of the 17 patients assessable for toxicity, two experienced
neutropaenia Grade 3 (Table 2). There was one episode of Grade 4
neutropaenia in a patient who also had Grade 3 thrombocytopae-
nia and anaemia. There were also two other cases of Grade 3
thrombocytopaenia. Patients 5 and 10 required a 50% dose
reduction in temozolomide due to hematological toxicity, with
patient 11 requiring a 50% dose reduction in both drugs.
Nonhematological toxicities included arthralgia, nausea and
vaginal thrush. Two patients experienced an allergic reaction to
Taxol, but in only one of these did this limit treatment.
Of the 15 patients assessable for response, there were two partial
responses. Patient 1, who had primary disease in the gall bladder
with liver secondaries, showed a sustained response with no
evidence of progressive disease after nine cycles. At 4 years after
starting the trial, the patient remains well with only minimal
evidence of liver disease. Patient 206, whose primary site was the
skin of the left shoulder, with some deposits in the left axiliary
lymph node, was treated initially on dose level 6. She had a partial
response after two cycles, which was sustained on CT scan after a
further four cycles of treatment. This patient subsequently suffered
Table 1 Patient summary
Patient Dose level Gender Age (years) Clinical outcome
1 1 F 51 Excellent response to treatment, had nine cycles
2 1 F 62 PD after C2
3 1 F 57 PD after C4
4 2 M 31 Withdrawn due to brain metastases
5 2 F 41 Improvement in CT after C3, but PD after C5
6 2 M 55 PD after 22 days
7 2 M 37 After C6, MRI revealed cysts and no cancer
8 3 M 55 PD after 31 days
9 3 M 52 PD after C2
10 4 F 50 Minor response after C3. Withdrawn due to G4 thrombocytopenia after C4
11 4 F 52 Stopped after C2 due to haematoxocity and allergic reaction to taxol
12 4 F 66 PD after C3
201 4 M 65 PD after C2
13 4 F 38 Withdrawn due to brain metastases after C3
14 4 M 29 Not given treatment, bleeding lesion
202 4 M 53 PD after C2
203 5 M 68 Withdrawn due to brain metastases after C1
204 5 M 63 SD after C2 and C4, but withdrawn due to brain metastases after C4
205 5 M 54 Withdrawn due to brain metastases after C1
206 6 F 52 PR after C3, had six cycles in total
20 6 M 41 PD after C2
21 6 M 69 PD after C2
Patients were recruited at two centres, with different patient number schemes at each center. PD¼progressive disease; C2¼course 2, etc.; CT¼computerised tomography
scan; MRI¼magnetic resonance imaging scan; G4¼Grade 4, etc., M¼male; F¼female; PR¼partial response; SD¼stable disease.
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sa recurrence of disease 3 months after the end of treatment,
received radiotherapy and further chemotherapy including single
agent temozolomide, but died of disease progression nearly 2 years
after entry into this trial. In addition, patient 5 at dose level 2 and
patient 10 at dose level 4 had mixed or minor responses. Patient
204 had stable disease up to course 4, but was withdrawn from
study due to brain metastases.
Pharmacokinetic studies
Temozolomide was administered at three different doses (100, 150
and 200mgm
 2day
 1). Although four patients were treated with
150mgm
 2day
 1 temozolomide (combined with 150mgm
 2
paclitaxel), reliable pharmacokinetic data for temozolomide were
available from only one patient. One patient on dose level 3 at
200mgm
 2day
 1 had anomalous data, with increasing plasma
concentrations throughout the sampling period. A representative
graph of temozolomide and paclitaxel plasma concentrations in a
patient treated at dose level 3 is shown in Figure 2.
There was no significant difference among the estimates of half-
life, Cl/F or Vz/F for temozolomide at these different doses of
temozolomide (Table 3), with an apparent dose-linear increase in
AUC comparing doses between 100 and 200mgm
 2 (Table 3). The
different doses of paclitaxel (150, 175, 200 and 225mgm
 2)
administered in conjunction with the highest dose of temozolo-
mide (200mgm
 2) did not appear to influence the pharmacoki-
netics of the latter drug (data not shown). Comparing the
pharmacokinetics of temozolomide on day 1 (with paclitaxel)
and day 5 (without paclitaxel), there was no difference in Cmax or
AUC between the 2 days of study (Table 3).
A summary of the pharmacokinetic data for paclitaxel at each of
four dose levels is given in Table 4. Clearance of paclitaxel was
greater at the lowest dose level of 150mgm
 2 (6087211mlmin
 1,
all patients dose levels 1–3), compared to that observed at 175–
225mgm
 2 (3737100 to 3637120mlmin
 1). For dose levels 1–3,
where the paclitaxel dose was held constant, but the dose of
temozolomide varied from 100 to 200mgm
 2day
 1, there appears
to be an increase in paclitaxel clearance as the dose of
temozolomide was escalated (Table 4). However, the numbers of
patients at each dose level are small and one-way analysis of
variance on the log-transformed data indicated no significant
effect. Comparison of paclitaxel clearance from patients in the
current study with those from previously published studies
suggests that those patients at dose level 1 have an unusually low
clearance, while clearance values in patients at dose level 3 are
larger than expected (see below).
DISCUSSION
This investigation combines in vitro studies of temozolomide and
tubulin binding drugs with a Phase I clinical study of temozolo-
mide and paclitaxel in melanoma. Interest in the use of these two
agents in melanoma has been stimulated by their single-agent
activities (Wiernik and Einzig, 1993) and nonoverlapping toxicities
and mechanisms of resistance.
In vitro studies in two melanoma cell lines showed sensitivity to
temozolomide and paclitaxel in line with reported IC50 values for a
variety of other cell lines. Sensitivity to temozolomide is reported
to depend on the activity of the repair enzyme O
6-alklyguanine
alkyltransferase (ATase) and on mismatch repair (MMR) function
(Pepponi et al, 2003). While the MMR status of these cell lines is
not known, the relatively high IC50, coupled with the low ATase
activity of the A375P cell line (95fmolmg
 1 protein) (Wedge et al,
1997), may suggest a deficiency in MMR. Many tumour cells have
only a moderate sensitivity to temozolomide (IC50 around 10–
1000mM) (Taverna et al, 2000; Pepponi et al, 2003), with a greater
degree of sensitivity to paclitaxel (IC50 1–10nM) (Rowinsky and
Donehower, 1995; Lamendola et al, 2003). Resistance of melanoma
cell lines to temozolomide is associated with deficiencies in
mismatch repair and/or high activity of the repair enzyme O
6-
alkylguanine-DNA alkyltransferase (Pepponi et al, 2003). Interest-
ingly, these two melanoma cell lines were also sensitive to
epothilone B (IC50 0.3 and 0.5nM). In a Phase I study of epothilone
B, plasma concentrations exceeded 1nM for approximately 8h
(Rothermel et al, 2003).
The combination studies with temozolomide and either
paclitaxel or epothilone B showed strong signs of synergy. At the
higher dose combinations used, effectively all of the cells were
Table 2 Haematological and nonhaematological toxicity by dose level
Dose level No. of patients No. of cycles Haematological toxicities Nonhaem. toxicities Best responses
1 3 15 G2 neutropaenia G1 Arthralagia 1 PR
2 4 12 G3 anaemia Allergic reaction to taxol 1 MR
G3 thrombocytopaenia
3 2 3 G3 neutropaenia G2 Arth.
4 6 16 G4 neutropaenia 1; G3 neutropaenia 1 G2 Arth. 1 MR
G3 thrombocytopaenia 2; G3 anaemia  1 Allergy to taxol
5 3 5 G2 neutropaenia 1 SD
6 3 10 G2 neutropaenia 21 P R
PR¼partial response; MR¼mixed response; SD¼stable disease.
Patient 9



























































Figure 2 Time course of temozolomide (left axis) and paclitaxel (right
axis) plasma concentrations on day 1 of therapy. The oral dose of
temozolomide was administered first, with the 3h infusion of paclitaxel
started 60min later. Data from day 5 administration of temozolomide are
superimposed for comparison.
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skilled. The mechanism of such synergy may relate to the mitotic
block following paclitaxel or epothilone B treatment. It has been
suggested that cells become apoptotic following escape from G2M
blockade, and it may be that such cells are then sensitised to the
actions of alkylating agents such as temozolomide. Previous
studies have indicated additive effects of alkylating agents with
paclitaxel (Liebmann et al, 1994). Combinations of temozolomide
with tubulin binders such as the agents studied here have not been
reported previously and may show useful activity in other tumour
types. Although only two melanoma cell lines were studied, the
activity of these agents in combination, at clinically relevant
concentrations, indicates that further evaluation is warranted.
The clinical study, with a dose escalation of temozolomide
followed by escalation of paclitaxel, showed that in combination
both drugs could be given at full therapeutic doses. Indeed, the
toxicity experienced was relatively mild even at the highest dose of
paclitaxel (225mgm
 2) permitted by the protocol. Although grade




 2 paclitaxel), none occurred at the
subsequent higher dose levels. There was some evidence of
cumulative toxicity, with patient 10 at dose level 4 withdrawn
from treatment due to Grade 4 thrombocytopaenia after course 4.
Further dose escalation may be possible, but the clinical benefit of
this is unknown. A number of patients gained some clinical benefit
from treatment with temozolomide and paclitaxel. Patient 1
showed a good response and went on to receive nine courses of
treatment, remaining well on long-term follow-up. Patient 10 had a
minor response and patient 206 had a partial response after course
3, receiving six courses in total. Patient 7 received six courses of
treatment for what appeared to be a recurrence of liver metastases.
However, liver scans revealed the presence of benign cysts. In this
Phase I study, the primary aim was to determine the safety of
temozolomide and paclitaxel in combination. Nevertheless, the
level of activity observed, over a range of dose levels, is promising.
Other clinical studies of a combination of a taxane with
monofunctional alkylating agent have been reported. Paclitaxel
has been given at doses up to 250mgm
 2 with DTIC up to
1000mgm
 2. This combination was well tolerated, but did not
show a higher response rate than either agent used alone (Feun
et al, 2002). Similarly, docetaxel has been combined with DTIC, but
again the response rate was not dissimilar to single-agent therapy
(Bafaloukos et al, 2002a). The combination of temozolomide with
docetaxel has recently been reported to be safe and to have good
activity in a Phase II study (Bafaloukos et al, 2002b). Dacarbazine
may not be a good drug for use in these combinations as it requires
metabolic activation, which may be inhibited by coadministered
drugs such as the taxanes.
Recent clinical studies in malignant melanoma have explored
other schedules and combinations of these two drugs. Temozolo-
mide has been combined with thalidomide (Hwu et al, 2003) or
with interferon-a, using schedules similar to that used here, or with
daily or three-times daily administration for 6 weeks out of eight.
Most promising results have been obtained in combination with
thalidomide (Danson et al, 2003), but that combination requires
further investigation. Paclitaxel has been investigated on a weekly
schedule (Zimpfer-Rechner et al, 2003) or every 4 days for three
doses in a three week cycle. The latter schedule produced a 15%
response rate (Bedikian et al, 2004). Combinations with carbopla-
tin have also been investigated, but with no therapeutic benefit
(Zimpfer-Rechner et al, 2003). Given the results presented here,
exploration of other schedules for both drugs may be beneficial.
The combination of temozolomide with paclitaxel involves the
administration of one drug orally, while the other is given by a
continuous 3h infusion. The relative timings of the two drugs may
be governed by clinical concerns, such as withholding the oral
drug in case a hypersensitivity reaction is seen to the intravenous
one. Hypersensitivity reactions were seen in only two patients in
this study. Regardless of the order of administration, there is no a
priori reason to suspect a pharmacokinetic interaction between
temozolomide and paclitaxel. One is eliminated almost entirely by
a spontaneous chemical reaction, while the other is subject to
metabolism, mediated by CYP450 enzymes, and to biliary
excretion.
The pharmacokinetic parameters derived for temozolomide in
combination with paclitaxel were very similar to those reported
previously for temozolomide alone (Jen et al, 2000). Also, there
was no evidence of nonlinearity of pharmacokinetics as the dose of
temozolomide was increased and no effect of increasing the
concurrent dose of paclitaxel from 150 to 225mgm
 2. Although at
the lowest dose level of paclitaxel (150mgm
 2) there did appear to
be an increase in clearance with increasing dose of temozolomide
(100–200mgm
 2day
 1), this was not statistically significant.
Previous studies with paclitaxel at a dose of 150mgm
 2 indicated
a clearance of 588731mlmin
 1 (Siddiqui et al, 1997), almost
identical to that reported at dose level 2. At dose level 3, the two
patients with full paclitaxel data had unusually high clearances, but
Table 3 Temozolomide pharmacokinetic parameters




















 1) 241 157 54 1501
3–6 (n¼14) (200mgm
 2day
 1) 122755 188755 30.575.5 21067608 19467580 (n¼11)
F indicates bioavailability, which is not determined here. AUC is the area under the plasma concentration–time curve.
aData available on only one patient at this dose level. One
patient at 200mgm
 2day
 1 had anomalous data, with increasing plasma concentrations throughout the sampling period.
Table 4 Paclitaxel pharmacokinetic parameters
Dose level Half-life (min) Clearance (mlmin




 2) 470, 522 364, 430 247, 324 632, 600
2 (150mgm
 2) 502, 383 652, 513 473, 283 359, 480
3 (150mgm
 2) 550, 412, 105
a 779, 909, 505
a 619, 540, 76
a 385, 300, 523
a
4 (175mgm
 2) 410774 3737100 216753 8587255
5 (200mgm






 2) 298787 3637120 152763 12207416
aData only to 8h.
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sthe third patient, in whom data were available only to 8h, had an
approximate clearance value nearer to that expected. There was no
evidence of increased clearance of paclitaxel in combination with
the same dose of temozolomide at dose level 4. The expected
phenomenon of apparent decrease in clearance with increasing
dose of paclitaxel was observed, which may cloud the interpreta-
tion of any apparent interaction. This apparent nonlinearity in
pharmacokinetics is now known to be due to the action of the
solubilising agent Cremophor, which sequesters paclitaxel in a
dose-dependent manner (van Zuylen et al, 2001). In conclusion, in
the absence of a within patient crossover study, there appears to be
no pharmacokinetic interaction between temozolomide and
paclitaxel when given in combination.
The in vitro data presented here indicate that the combination of
temozolomide with the microtubule agent epothilone B or
paclitaxel produces a synergistic inhibition of tumour cell growth.
The clinical study of the combination of temozolomide with
paclitaxel shows that this combination is well tolerated, not
complicated by any pharmacokinetic interaction and has modest
activity in a Phase I setting. Although the response rate in this
Phase I study was not dissimilar to that of the individual agents,
the combination of the two drugs at full therapeutic doses could be
investigated further. Combinations of temozolomide with epothi-
lone B may also be beneficial, but require initial clinical evaluation.
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